נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Halofuginone prevents subglottic stenosis in a canine model
Year:
2006
Authors :
Pines, Mark
;
.
Volume :
115
Co-Authors:
Eliashar, R., Department of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel, Dept. of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Ochana, M., Liver Laboratory, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Maly, B., Department of Pathology, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Pines, M., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
Sichel, J.-Y., Department of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Nagler, A., Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Facilitators :
From page:
382
To page:
386
(
Total pages:
5
)
Abstract:
Objectives: Halofuginone is a low-molecular weight quinazolinone alkaloid coccidiostat that inhibits collagen type I synthesis, extracellular matrix deposition, and angiogenesis. This study was conducted to assess its potential in preventing subglottic stenosis (SGS). Methods: We induced SGS in 10 dogs randomly divided into 2 groups. Each group received treatment between 3 days before and 21 days after the induction of SGS. One group received oral halofuginone 40 μg/kg, and the other was given placebo. The area of the subglottic lumen was measured at baseline and 3 months later. In addition, human tracheal fibroblasts were cultured. The inhibitory effect of halofuginone was compared to the effect of mitomycin. Results: All dogs survived throughout the study with no side effects. Three months after the operation, no halofuginone-treated dog had SGS, in contrast to a 66% to 80% stenosis rate (mean, 72%) in controls (p < .008). Thick fibrotic tissue was found in the placebo-treated larynges, whereas an almost normal architecture was observed in halofuginone-treated larynges. Halofuginone inhibited the growth of human tracheal fibroblasts by 75%, in comparison with 60% inhibition by mitomycin (no statistically significant difference). Conclusions: This preliminary study shows that halofuginone is effective in preventing SGS caused by an acute injury. Halofuginone has a potential therapeutic role in preventing SGS in humans. © 2006 Annals Publishing Company. All rights reserved.
Note:
Related Files :
animal experiment
animal model
Animals
animal tissue
Fibrosis
human cell
Mitomycin
quinazolinone derivative
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
28513
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:39
Scientific Publication
Halofuginone prevents subglottic stenosis in a canine model
115
Eliashar, R., Department of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel, Dept. of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Ochana, M., Liver Laboratory, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Maly, B., Department of Pathology, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Pines, M., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
Sichel, J.-Y., Department of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel
Nagler, A., Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Halofuginone prevents subglottic stenosis in a canine model
Objectives: Halofuginone is a low-molecular weight quinazolinone alkaloid coccidiostat that inhibits collagen type I synthesis, extracellular matrix deposition, and angiogenesis. This study was conducted to assess its potential in preventing subglottic stenosis (SGS). Methods: We induced SGS in 10 dogs randomly divided into 2 groups. Each group received treatment between 3 days before and 21 days after the induction of SGS. One group received oral halofuginone 40 μg/kg, and the other was given placebo. The area of the subglottic lumen was measured at baseline and 3 months later. In addition, human tracheal fibroblasts were cultured. The inhibitory effect of halofuginone was compared to the effect of mitomycin. Results: All dogs survived throughout the study with no side effects. Three months after the operation, no halofuginone-treated dog had SGS, in contrast to a 66% to 80% stenosis rate (mean, 72%) in controls (p < .008). Thick fibrotic tissue was found in the placebo-treated larynges, whereas an almost normal architecture was observed in halofuginone-treated larynges. Halofuginone inhibited the growth of human tracheal fibroblasts by 75%, in comparison with 60% inhibition by mitomycin (no statistically significant difference). Conclusions: This preliminary study shows that halofuginone is effective in preventing SGS caused by an acute injury. Halofuginone has a potential therapeutic role in preventing SGS in humans. © 2006 Annals Publishing Company. All rights reserved.
Scientific Publication
You may also be interested in